Formulation Development Forum - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Formulation Development Forum
Analysis of crospovidone as a superdistingrant.


Pharmaceutical Technology
Volume 35, Issue 1, pp. 50

The issue of peroxide contamination in crospovidone was recently underscored when the US Food and Drug Administration issued an advisory to manufacturers of drugs and dietary supplements to apprise them of a contaminated lot of crospovidone from a Chinese supplier (2). The peroxide level found by FDA in the lot was more than four times the maximum level of peroxide (400 ppm) allowed by global compendial monographs. FDA issued the advisory because it was "concerned that drug manufacturers using excipients containing high levels of peroxides will observe a loss of drug potency and the formation of excessive impurities during the product shelf life" (2). FDA advised manufacturers to use sound risk-management principles when working with a supplier of crospovidone to ensure the quality of the product.

In terms of functionality, commonly used superdisintegrants such as crospovidone, croscarmellose sodium, and sodium starch glycolate are effective at low concentration levels (2–5 w/w%) in tablet formulation by facilitating the rate and extent of tablet disintegration (3). Bee points out, however, that although these excipients are often comparable with respect to disintegration, there can be differences in dissolution. As a nonionic compound, crospovidone can be more effective with cationic active ingredients, an advantage compared with anionic disintegrants such as croscarmellose sodium and sodium starch glycolate, which would interact with the cationic actives and potentially retard dissolution. In one recent study, for example, ISP evaluated the respective effects of crospovidone, croscarmellose sodium, and sodium starch glycolate on the dissolution behavior of eight cationic drugs from a model direct-compression tablet formulation with 2% w/w superdisintegrant (3). Although no significant differences were observed in the disintegration times of the tablets, the study showed that actives formulated with crospovidone showed a more rapid dissolution rate than the same drugs formulated with other superdisintegrants for the cationic drugs studied, irrespective of the drug's aqueous solubility (3).

In a separate study, ISP evaluated the impact of the superdisintegrant on the dissolution of 13 poorly soluble drugs (4). Although no significant differences were observed in the disintegration times of the tablets, the study showed that actives formulated with crospovidone showed a more rapid dissolution rate than the same drugs formulated with other superdisintegrants for 12 of the 13 poorly soluble drugs studied.

Sources

1. Ph. Eur. 7.0 (Strasbourg, France), 1771–1773 (2011).

2. FDA, "Advisory to Drug and Dietary Supplement Manufacturers, Compounding Pharmacies and Distributors of Excipients and Dietary Ingredients—FDA Detects High Levels of Peroxide in Crospovidone" (Rockville, MD, Oct. 21, 2010).

3. J. Balasubramaniam et al., Dissolution Technol. 15 (2), 18–25 (2008).

4. J. Balasubramaniam and T. Bee, Pharm. Technol. 33 (4) supp. Excipient Performance for Solid Dosage Forms, s6–s14 (2009).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
22%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
11%
Regulatory compliance
37%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here